Effects of an oral supplementation of germinated barley foodstuff on serum tumour necrosis factor-α, interleukin-6 and -8 in patients with ulcerative colitis
dc.contributor.author | Faghfoori, Z | |
dc.contributor.author | Navai, L | |
dc.contributor.author | Shakerhosseini, R | |
dc.contributor.author | Somi, MH | |
dc.contributor.author | Nikniaz, Z | |
dc.contributor.author | Norouzi, MF | |
dc.date.accessioned | 2018-08-26T08:52:57Z | |
dc.date.available | 2018-08-26T08:52:57Z | |
dc.date.issued | 2011 | |
dc.identifier | 10.1258/acb.2010.010093 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53844 | |
dc.description.abstract | Background: The efficacy of germinated barley foodstuff (GBF) on tumour necrosis factor-alpha (TNF-?), interleukin-6 (IL-6) and -8 (IL-8) in patients with ulcerative colitis (UC) has not yet been examined. The aim of the present study was to determine the effect of administration of GBF on serum TNF-?, IL-6 and -8 levels in UC patients in remission. Methods: Forty-one patients with UC were divided into two groups, namely control and GBF group. Twenty-one patients in the control group received standard treatment while 20 patients in the GBF group received 30 g of GBF daily by oral administration during two months of the study along with standard drug therapy. Results: Levels of TNF-?, IL-6 and -8 all decreased in the GBF group compared with baseline during the two-month study, while in the control group all values rose. For IL-6 and -8 this effect was significant, P = 0.034 and 0.013, respectively. Conclusions: The results of the present study showed that the consumption of GBF may reduce the level of serum TNF-?, IL-6 and -8 in patients with UC. This investigation was designed as a pilot study and the results may provide a basis for more future clinical trials. | |
dc.language.iso | English | |
dc.relation.ispartof | Annals of Clinical Biochemistry | |
dc.subject | germinated barley foodstuff | |
dc.subject | interleukin 6 | |
dc.subject | interleukin 8 | |
dc.subject | prebiotic agent | |
dc.subject | tumor necrosis factor alpha | |
dc.subject | unclassified drug | |
dc.subject | article | |
dc.subject | barley | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | female | |
dc.subject | human | |
dc.subject | inflammation | |
dc.subject | male | |
dc.subject | priority journal | |
dc.subject | remission | |
dc.subject | ulcerative colitis | |
dc.subject | Administration, Oral | |
dc.subject | Adult | |
dc.subject | Colitis, Ulcerative | |
dc.subject | Dietary Supplements | |
dc.subject | Female | |
dc.subject | Germination | |
dc.subject | Hordeum | |
dc.subject | Humans | |
dc.subject | Interleukin-6 | |
dc.subject | Interleukin-8 | |
dc.subject | Male | |
dc.subject | Prebiotics | |
dc.subject | Recurrence | |
dc.subject | Tumor Necrosis Factor-alpha | |
dc.subject | Hordeum | |
dc.title | Effects of an oral supplementation of germinated barley foodstuff on serum tumour necrosis factor-α, interleukin-6 and -8 in patients with ulcerative colitis | |
dc.type | Article | |
dc.citation.volume | 48 | |
dc.citation.issue | 3 | |
dc.citation.spage | 233 | |
dc.citation.epage | 237 | |
dc.citation.index | Scopus |